Our website uses cookies to distinguish you from other users of our site. This helps us to continually improve your experience when using our website. We also use external analytics software which may set additional cookies to perform their analysis. These cookies (and any others in use) are detailed in our site Privacy and Cookie Policies. You can delete or disable these cookies in your web browser at any time but doing so may impact website functionality and user experience.

Dr Anne Dobrée Dr Anne Dobrée Head of Seed Funds
As Head of Seed Funds at Cambridge Enterprise, Anne has overseen strong growth in our investment activities, with Seed Funds investing over £5 million each year in young companies.

Recent highlights include the purchase of Cambridge CMOS Sensors by ams, and the sale of Quethera to Astellas Pharma. Anne has also served on many boards including those of Cambridge CMOS Sensors, Aqdot, Cambridge Touch Technologies, Psyomics, MorphoenIX and Quethera. She was a founding member of Praxis Auril, which supports Knowledge Exchange Commercialisation in the UK.

Anne’s early career includes experience in technology transfer at Imperial College Innovations Limited, in pharmaceutical development at Evans Medical, and in pharmaceutical product training at Information Transfer.

Anne holds a BSc in Medical Microbiology and a PhD in Immunology.

Anne joined the technology transfer team at the University of Cambridge in 2001, and has been involved with Cambridge Enterprise since its foundation in 2006, including as Interim Director just prior to this. She joined the Seed Funds team in 2008 and was appointed Head of Seed Funds in 2011.